Despite a failed bone marrow transplant, Delhi’s dr (col) vk gupta beat his blood canser after receiving car t-celpey ata memorial hospital. Not only did he recover, he was about to go back to work in his outpatient clinic. He is gang those who has been before this cutting edge cancer treatment that re-engineers the body’s own immune cells, enabling them to fight the cancer own. Can Thisopy Now Work For Solid and Hard-To-TrAT Tumours as well?

Earllier this month, there was good news on this front with two studies indicating in life span. Positive Results from the first ever phase Ii trial of car t-cell Therapy for solid cancers-Those in the form of gastrointestinal tumors-was published from china. Another Early Study on the impact of a double target car t-cell Therapy on a very different-toat brain cancer was also published in the us. “With so many people working on the problem, it is possible that we can see some car t-cell Therapy for solid cancers. Is good when survival otherwise is just a couple of months He collaborated with the IIIT Bombay Team that is developed the country’s first car t-cell therapy.

What is car t-cell therapy and how do it work?

Car T-Cell Therapy essentially uses a cancer patient’s own immune t-mills and engineers them in a laboratory to address that can bind specifically with the canser cells. These engineered cells are then multiplied and infused in the patient. Usually, the canserous cells have the availability to hide from the unmodified t-sells. Howver, with the new receptors on the t-sells, they cannot. The body’s immune system then kills the cancer cells.

Story Continues Below this ad

Why are solid cancers more different to treat using this method?

This, Experts say, is because it is much more different to target solid cancers than blood caners. “One of the biggest problems with car t-cell Therapy for solid cancers are there areas. There are cases of pulmonary toxicity in the small quantities, the brca gene mutations in the breast. Well, “Says Dr Mayank Singh, Associate Professor of Medical Oncology at Aiims-New Delhi.

Another Challenge is that the same type of cancer may be molecularly very different patients – or even without the same patient – Making It Extremely DIFFICULT TO FIND A Suite Target.

Besides, solid tumors are a more complex disease, say dr jain. “Unlike Blood Cancers, Other Cancers are not in the blood Microenvironment or the immediate area round the tumor, “He explains. This is hostile towards immune cells and can deactivate them, including the modified T-Cells give to patients.

What did the two recent studies show?

The phase ii study from china showed that outcome was better with the new car t as compared to the therapy generally prescribed by the physician. Patients with gastrointestinal cansrs carrying a specific mutation called CLDN18.2 – Have been remembived two unsuccessful treatments previously —Were Given the new therapy or existing trends. The study found that 35 per cent

Story Continues Below this ad

Those on the new therapy also lived 2.4 months longer on average as compared to the control group.

Another New Car T-Cell Therapy, which used two targets instead for a very different to treat brain tumor called glioblastoma, showed promise in a trial condom in a trial condom at universelvania. The tumors became small in nearly two-thirts And, Several of the Patients have already lived 12 months or longer, which is significant consider that people with this type of cancer typically survive online for six to ten.

Importantly, The Researchers Also Found Evidence to Suggest that modified t-sells remained in the patients’ immune system and continned to prevent tumor growsth over time.

What is the status of car t research on solid tumors acros the world?

Experts say that studies on brain and spinal cansrs called gliomas and those targeting cldn18.2 are probably at the most advanced stages of development of development and may be approved with a fine year. “Now, Researchers are using Ai to Identify Suitable Targets for Car T Therapies.

Story Continues Below this ad

Are Indian Companies Working on Solid Tumours?

The IIIT Bombay-Incubated Start-Upp Immunoact is also working on a therapy that can work on brain and nerve cell cancer calls glioblastoma and neuroblastoma. Another therapy that it is pursuing will work on the gastroesophageal junction cansrs – The same cancer as the chinese trial locked at.

Anonna Dutt is a principal correspondent who writes primarily on health at the Indian express. She Reports on Myriad Topics Ranging from the growing burden of non-compromunicable diseases such as diabetes and hypertension to the problem with pervasive infectious conditions. She Reported on the Government’s Management of the Covid-19 Pandmic and Closely followed the Vaccination Program. Her stories have results in the city government investing in high-end tests for the poore and acknowledging errors in their official reports. Dutt also take a keeps in the country’s space program and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was Among the first batch of Eleven Media Felows with RBM Partnership to End Malaria. She was also selected to participle in the short-trm program on Early Childhood Reporting at Columbia University’s Dart Center. Dutt has a bachelor’s degree from the Symbiosis Institute of Media and Communication, Pune and A PG Diploma from the asian college of journalism, chennai. She started her reporting career with the hindustan times. When not at work, she tries to appease the duolingo owl with her freench skills and sometimes take to the dance floor. … Read more